Alan Hambelton

Cooley advised Zillow Group, a company reimagining real estate to make home a reality for more people, on its definitive agreement to acquire Follow Up Boss, a customer relationship management system for real estate professionals, for $400 million in initial cash consideration and up to $100 million in a potential cash earnout.

Cooley advised Dutch Bros, a publicly held drive-thru coffee chain, on its $300 million underwritten public offering of Class A common stock.

Cooley advised biopharmaceutical company Cytokinetics on its Rule 144A offering of $450 million aggregate principal amount of 3.50% convertible senior notes due in 2027, which includes the full exercise of the initial purchasers’ option to purchase an additional $90 million aggregate principal amount of notes. Lawyers Robert Jones, Mischi a Marca, Alan Hambelton, Jason Savich, Julia Stark, Justine Chiu and Hailey Yook led the Cooley team advising Cytokinetics.

Cooley advised Dutch Bros, a drive-thru coffeehouse chain, on its $556.8 million initial public offering of 24,210,526 shares of its common stock. Partners Eric Jensen, Alan Hambelton and Dave Peinsipp led the Cooley team advising Dutch Bros.

Cooley advised Eliem Therapeutics on its $92 million initial public offering of 7,360,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Eliem Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol ELYM, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Partners Alan Hambelton, Sonya Erickson and Stephen Rosen led the Cooley team.